LONDON, Feb 5 (Reuters) - AstraZeneca expects results from
the U.S. clinical trial of its COVID-19 vaccine in the next four
to six weeks, the pharma firm's research chief Mene Pangalos
said on Friday.
Asked about when the U.S. trial results would be ready,
given high transmission rates during the trial, Pangalos said
that they had been high during "the latter period of the trial".
"I think we're getting very close to getting data. I would
say in the next four to six weeks we should have the results for
that study reading out," he told reporters.
Some experts had expected the data sooner than that, given
the high infection rates in the United States during the period
of testing.
(Reporting by Alistair Smout and Kate Kelland; editing by
Michael Holden)
Astrazeneca (AZN)
